US Teen Invents Soap To Treat Skin Cancer, To Cost Less Than $10
Heman Bekele, a 14-year-old boy from the United States, studying at Fairfax County's Frost Middle School, has invented a soap that could help fight skin cancer. He has been named America's Top Young Scientist after competing with nine other people in the 2023 3M Young Scientists Challenge. He also…#hemanbekele #fairfaxcounty #frostmiddleschool #heman #ethiopia #deborahisabelle (Source: Reuters: Health)
Source: Reuters: Health - October 25, 2023 Category: Consumer Health News Source Type: news
US student, 14, wins award for developing soap to treat skin cancer
Heman Bekele was inspired by Ethiopian workers laboring under the sun, and wanted to help ‘as many people as possible’A middle-school teen has been named “America’s top young scientist” after developing a bar of soap that could be useful in the treatment of melanoma, a skin cancer that isdiagnosed in about 100,000 people in the US each year and kills approximately 8,000.Heman Bekele, a 14-year-old ninth grader from Annandale, Virginia, won the award after beating out nine other finalists.Continue reading... (Source: Guardian Unlimited Science)
Source: Guardian Unlimited Science - October 25, 2023 Category: Science Authors: Edward Helmore Tags: Cancer Science US news Health World news Source Type: news
Melanoma Updates From ASCO 2023: PD-1 and LAG-3 Melanoma Updates From ASCO 2023: PD-1 and LAG-3
Jeffrey S. Weber, MD, PhD, discusses updates related to melanoma practice and care from ASCO 2023.Medscape Oncology (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - October 24, 2023 Category: Cancer & Oncology Tags: Hematology-Oncology Commentary Source Type: news
Tebentafusp's OS Benefit in Uveal Melanoma Holds Up at 3 Years
(MedPage Today) -- MADRID -- The significant survival benefit with the bispecific T-cell receptor therapy tebentafusp (Kimmtrak) held up at 3 years for selected patients with previously untreated metastatic uveal melanoma, updated results of... (Source: MedPage Today Dermatology)
Source: MedPage Today Dermatology - October 22, 2023 Category: Dermatology Source Type: news
Three-Year Overall Survival with Tebentafusp in Metastatic Uveal Melanoma
(Source: Reuters: Health)
Source: Reuters: Health - October 22, 2023 Category: Consumer Health News Source Type: news
Society for Immunotherapy of Cancer Publishes Clinical Practice Guideline Immunotherapy for Melanoma, V3.0
The Society for Immunotherapy of Cancer (SITC), the world's leading member-driven organization dedicated to improving patient outcomes by advancing the science and application of cancer immunotherapy, is pleased to announce the publication of a new clinical practice guideline (CPG)... (Source: PRWeb: Medical Pharmaceuticals)
Source: PRWeb: Medical Pharmaceuticals - October 20, 2023 Category: Pharmaceuticals Tags: SVY Source Type: news
AI Can Flag Skin Cancer With Near-Perfect Accuracy AI Can Flag Skin Cancer With Near-Perfect Accuracy
Artificial intelligence could help dermatologists catch skin cancer faster and triage patients.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - October 20, 2023 Category: Consumer Health News Tags: Dermatology News Source Type: news
Beverley woman's 'complete shock' at skin cancer misdiagnosis
Megan Royle, 33, from Beverley, underwent surgery after being wrongly told she had skin cancer. (Source: BBC News | Health | UK Edition)
Source: BBC News | Health | UK Edition - October 18, 2023 Category: Consumer Health News Source Type: news
FDA Approves Nivolumab as Adjuvant Treatment for Melanoma
WEDNESDAY, Oct. 18, 2023 -- The U.S. Food and Drug Administration has approved Opdivo (nivolumab) for the adjuvant treatment of completely resected stage IIB/C melanoma in patients ages 12 years and older.
The approval was based on results from the... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - October 18, 2023 Category: Pharmaceuticals Source Type: news
Episode 6: The Management of Melanoma in Community Oncology Practice Episode 6: The Management of Melanoma in Community Oncology Practice
Drs Patel, Wright, and Devoe revisit their involvement in the SWOG S1801 trial to highlight available resources that can expand the reach of cancer care in the community oncology setting.Medscape (Source: Medscape General Surgery Headlines)
Source: Medscape General Surgery Headlines - October 18, 2023 Category: Surgery Tags: Hematology-Oncology InDiscussion Source Type: news
NHS doctor warns of the little known skin cancer signs to check for on your body
As Brits wave goodbye to summer, NHS GP Doctor Dan Mullarkey reinforces the need to check all over your skin for signs of cancer. (Source: Daily Express - Health)
Source: Daily Express - Health - October 18, 2023 Category: Consumer Health News Source Type: news
FDA Approves Nivolumab for Resected Stage IIB/C Melanoma FDA Approves Nivolumab for Resected Stage IIB/C Melanoma
The new approval expands the melanoma indication for nivolumab to earlier-stage disease.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - October 16, 2023 Category: Consumer Health News Tags: Hematology-Oncology News Alert Source Type: news
FDA approves nivolumab for adjuvant treatment of Stage IIB/C melanoma
On October 13, 2023, the Food and Drug Administration approved nivolumab (Opdivo, Bristol-Myers Squibb Company) for the adjuvant treatment of completely resected Stage IIB/C melanoma in patients 12 years and older. (Source: FDA Center for Drug Evaluation and Research - What's New)
Source: FDA Center for Drug Evaluation and Research - What's New - October 16, 2023 Category: Drugs & Pharmacology Authors: FDA Source Type: news
Sun Pharma partner's skin cancer drug demonstrates efficacy against skin cancer
Sun Pharma's partner, Philogen, has reported positive results in late-stage clinical trials for its new drug, Nidlegy, which is used to treat skin cancers. In the trial, Nidlegy demonstrated a statistically significant improvement in recurrence-free survival for patients with resectable melanoma. The study compared Nidlegy followed by surgery with surgery alone. The treatment arm showed a reduction in the hazard risk ratio, and treatment-related adverse events were reported to be benign and manageable. Nidlegy is also being developed for the treatment of other types of skin cancers. (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - October 16, 2023 Category: Pharmaceuticals Source Type: news
U.S. Food and Drug Administration Approves Opdivo (nivolumab) as Adjuvant Treatment for Eligible Patients with Completely Resected Stage IIB or Stage IIC Melanoma
In the Phase 3 CheckMate -76K trial, Opdivo demonstrated a statistically significant improvement in recurrence-free survival compared to placebo1
CheckMate -76K marks the fifth Opdivo-based indication in earlier stages of cancer, in the... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - October 13, 2023 Category: Drugs & Pharmacology Source Type: news
